EDN1 and breast carcinoma: ET-1 is thought to progress tumours in colon, as well as ovarian, prostate, lung, bladder and breast cancers, via various mechanisms, including cell proliferation, resistance to apoptosis, angiogenesis, immune response modulation and metastasis, with evidence for the ETA receptor activity playing a key role [72].